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accumulation within hepatocytes and ranges from simple steatosis to steatohepatitis, which often progresses into advanced fibrosis and cirrhosis (Finelli and Tarantino 2012) . Liver has an important role in detoxification and is a crucial target of the toxicity of drugs and xenobiotics (Jaeschke et al. 2002) . Liver damage due to facultative hepatotoxins is scarcely foreseeable. NAFLD conveys a nearly fourfold increase of drug-induced liver injury risk in obese middle-aged patients (Tarantino et al. 2007 ).
Previous reports have suggested that ciliary neurotrophic factor (CNTF) or CNTF analogs ameliorated the metabolic abnormalities (Liu et al. 2007; Rezende et al. 2012 ) including fatty liver in obese mice (Cui et al. 2010; Sleeman et al. 2003) . The therapeutic effect is accompanied by improved liver function and antioxidant ability. In order to further clarify the underlying mechanisms of CNTF against obesity-related hepatic steatosis and whether CNTF could relieve the liver injury which induced by hepatotoxin, the present study induced acute hepatic injury by carbon tetrachloride (CCl 4 ) in rats and investigated the effects of a recombinant mutant of human CNTF (rhmCNTF).
CNTF activates leptin-like pathways and reduces body fat (Lambert et al. 2001) . But excessively high doses of CNTF can signal through receptors for related cytokines, such as IL-6 (Schuster et al. 2003) which can induce stress responses and cachexia (Lambert et al. 2001; Schooltink et al. 1992) and is strongly associated with fatty liver and steatohepatitis D r a f t 4 (Tarantino et al. 2009 ). Taking into account the immune adverse effects of CNTF, a safe and effective dose of rhmCNTF, 0.1 mg/kg/d, was used in the present study.
Materials and Methods
Animals and drug. Twenty-five male SPF Wistar rats (9-week-old) were obtained from Slac Inc. (Shanghai, China), housed in standard environmental conditions, and had free access to tap water and standard rodent chow. All animals were cared for in accordance with the Guide to the Care and Use of Experimental Animals (CCAC 1993) . RhmCNTF in the form of a freeze-dried powder injection was a gift from Lanzhou Institute of Biological Products (Lanzhou, China). The purity of this protein is higher than 95%. Statistical analysis. The data are expressed as mean ± S.D. Statistical comparisons between groups were analyzed by a two-tailed Student's t-test. P < 0.05 was considered significant.
Results and Discussion
CCl 4 -induced liver injury is a commonly used experimental model for hepatoprotective drug studying (Tlili et al. 2016; Wu et al. 2016) . In the present study, CCl 4 s.c. injection three One week after CCl 4 -cessation, the degree of hepatic steatosis was attenuated obviously.
Increased serum liver enzymes were also recovered but still much higher than that of control rats. These results showed that liver function which was damaged by CCl 4 was partly improved after CCl 4 -cessation one week later. The recovery of liver TP production led to a large amount of lipids, especially cholesterol, transferred from liver to peripheral blood. As a result, serum lipids level was increased while liver lipids accumulation was attenuated.
Serum TC, HDL-C, and LDL-C levels even rebounded and were much higher than that of CCl 4 . These findings indicate that rhmCNTF enhances systemic antioxidant capacity and protects rats against CCl 4 -induced oxidative stress. However, the effect of rhmCNTF on hepatic antioxidant activity needs further study.
In conclusion, the present study suggests that rhmCNTF has protective effect against CCl 4 -induced hepatic injury after CCl 4 -cessation. But hepatic steatosis and injury could be aggravated when combine rhmCNTF treatment with CCl 4 .
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